Effects of glucagon-like peptide-1 in diabetic rat small resistance arteries

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 3, 2014, Pages 277-284

  Bayram, Zeliha ^a   Nacitarhan, Cahit ^a   Ozdem, Sadi S ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Diabetes mellitus; Endothelium derived hyperpolarizing factor; Glucagon like peptide 1; Nitric oxide; Potassium channels; Resistance artery

Indexed keywords

APAMIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CHARYBDOTOXIN; EXENDIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HORMONE RECEPTOR BLOCKING AGENT; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; CYCLIC GMP; FAMPRIDINE; GLIBENCLAMIDE; GLUCAGON-LIKE PEPTIDE 1 (7-36); GLUCAGON-LIKE PEPTIDE-1 (9-36)-AMIDE; PEPTIDE; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ARTERY; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; WISTAR RAT;

4-AMINOPYRIDINE; ANIMALS; APAMIN; ARTERIES; CHARYBDOTOXIN; CYCLIC GMP; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; GLUCAGON-LIKE PEPTIDE 1; GLYBURIDE; MALE; NITRIC OXIDE; PEPTIDE FRAGMENTS; PEPTIDES; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 84929939879     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000120     Document Type: Article

References (40)

1. Tahrani AA, Piya MK, Kennedy A, et al. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther. 2010; 125: 328-361.
2. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992; 326: 1316-1322.
3. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 1996; 39: 1546-1553.
4. Gutzwiller JP, Goke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999; 44: 81-86.
5. Mannucci E, Ognibene A, Cremasco F, et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med. 2000; 17: 713-719.
6. Tolessa T, Gutniak M, Holst JJ, et al. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest. 1998; 102: 764-774.
7. Richter G, Feddersen O, Wagner U, et al. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol. 1993; 265(4 pt 1): L374-L381.
8. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995; 358: 219-224.
9. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996; 137: 2968-2978.
10. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol. 1994; 266(3 pt 1): E459-E466.
11. Barragan JM, Eng J, Rodriguez R, et al. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol. 1999; 277(5 pt 1): E784-E791.
12. Nikolaidis LA, Elahi D, Shen YT, et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005; 289: H2401-H2408.
13. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004; 287: E1209-E1215.
14. Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol. 2011; 108(suppl 3): 33B-41B.
15. Meier JJ, Gethmann A, Nauck MA, et al. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab. 2006; 290: E1118-E1123.
16. Golpon HA, Puechner A, Welte T, et al. Vasorelaxant effect of glucagonlike peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept. 2001; 102: 81-86.
17. Nyström T, Gonon AT, Sjoholm A, et al. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005; 125: 173-177.
18. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117: 2340-2350.
19. Green BD, Hand KV, Dougan JE, et al. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys. 2008; 478: 136-142.
20. Nathanson D, Erdogdu O, Pernow J, et al. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept. 2009; 157: 8-13.
21. Rotondo A, Amato A, Lentini L, et al. Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides. 2011; 32: 60-64.
22. Dong Z, Chai W, Wang W, et al. Protein kinase A mediates glucagonlike peptide 1-induced nitric oxide production and muscle microvascular recruitment. Am J Physiol Endocrinol Metab. 2013; 304: E222-E228.
23. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res. 1977; 41: 19-26.
24. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998; 97: 1695-1701.
25. Ozkan MH, Uma S. Inhibition of acetylcholine-induced EDHF response by elevated glucose in rat mesenteric artery. Life Sci. 2005; 78: 14-21.
26. Ban K, Kim KH, Cho CK, et al. Glucagon-like peptide (GLP)-1(9-36) amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology. 2010; 151: 1520-1531.
27. Ding L, Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin. 2012; 33: 75-81.
28. Crane GJ, Gallagher N, Dora KA, et al. Small- and intermediateconductance calcium-activated K+ channels provide different facets of endothelium-dependent hyperpolarization in rat mesenteric artery. J Physiol. 2003; 553(pt 1): 183-189.
29. MacKenzie A, Cooper EJ, Dowell FJ. Differential effects of glucose on agonist-induced relaxations in human mesenteric and subcutaneous arteries. Br J Pharmacol. 2008; 153: 480-487.
30. Lash JM, Bohlen HG. Structural and functional origins of suppressed acetylcholine vasodilation in diabetic rat intestinal arterioles. Circ Res. 1991; 69: 1259-1268.
31. Taylor PD, McCarthy AL, Thomas CR, et al. Endothelium-dependent relaxation and noradrenaline sensitivity in mesenteric resistance arteries of streptozotocin-induced diabetic rats. Br J Pharmacol. 1992; 107: 393-399.
32. Xu G, Kaneto H, Laybutt DR, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes. 2007; 56: 1551-1558.
33. Pan QR, Li WH, Wang H, et al. Glucose, metformin, and AICAR regulate the expression of G protein-coupled receptor members in INS-1 beta cell. Horm Metab Res. 2009; 41: 799-804.
34. Artinian SB, Al Lafi SM, Boutary SS, et al. Assessment of glucagon-like peptide-1 analogue and renin inhibitor on the binding and regulation of GLP-1 receptor in type 1 diabetic rat hearts. Exp Diabetes Res. 2011; 2011: 489708.
35. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996; 19: 257-267.
36. Diederich D, Skopec J, Diederich A, et al. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol. 1994; 266(3 pt 2): H1153-H1161.
37. Rodriguez-Manas L, Angulo J, Peiro C, et al. Endothelial dysfunction and metabolic control in streptozotocin-induced diabetic rats. Br J Pharmacol. 1998; 123: 1495-1502.
38. Wohaieb SA, Godin DV. Alterations in free radical tissue-defense mechanisms in streptozocin-induced diabetes in rat. Effects of insulin treatment. Diabetes. 1987; 36: 1014-1018.
39. Martin-Gallan P, Carrascosa A, Gussinye M, et al. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med. 2003; 34: 1563-1574.
40. Ceriello A, Quagliaro L, D'Amico M, et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes. 2002; 51: 1076-1082.